OTX-003

OTX-003 is a preclinical-stage radiopharmaceutical being developed by OncoBone Therapeutics for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) and other bone-metastasizing malignancies. The drug is developed using an osteoimmuno-oncology (OIO) approach, which focuses on the complex interactions between cancer cells, the bone microenvironment, and the immune system. OTX-003 is part of OncoBone's internal proprietary pipeline and is currently undergoing proof-of-concept studies. The company's business model involves advancing such assets to an IND-ready stage using their specialized Bone Metastasis Technology Platform before out-licensing to larger pharmaceutical partners for clinical trials.